Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum

Summary

A randomized, double-blind, placebo-controlled, multicenter, adaptive phase III trial to investigate efficacy and safety of vilobelimab in the treatment of ulcerative pyoderma gangrenosum

Timeline

Start

2023-11-01

Primary completion

2025-07-11

Completion

2025-07-11

Outcome

Missed primary endpoint

Stopped: “Study stopped for futility”

release “the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint” inflarx.de ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	vilobelimab	Monoclonal antibody	—	Intravenous

Indications